

MAYO CLINIC

METHOD CHANGE NOTIFICATION DATE: January 12, 2011 Immediately **EFFECTIVE DATE:**

Array Comparative Genomic Hybridization (aCGH), Whole Genome, Constitutional #88898

EXPLANATION: The Mayo Clinic Cytogenetics Laboratory has recently updated chromosomal microarray testing to utilize a platform containing 180,000 (180K) unique oligonucleotide probes (a 4-fold increase in probe density compared to the 44K array). Probes are spaced at ~ 25 kilobase intervals to provide backbone, genome-wide coverage, resulting in a functional resolution of approximately 100 kilobases throughout the genome. In addition, approximately 500 clinically relevant regions contain higher density, targeted oligonucleotide probe coverage. The increased probe density and additional targeted regions on this new platform will improve resolution and allow for the detection of additional clinically relevant copy number changes, ultimately improving patient care.

NOTE: Chromosomal microarray testing is now recommended by the American College of Medical Genetics as the first-tier test to detect chromosomal imbalances in individuals with developmental delay/intellectual disability, autism spectrum disorders, or multiple congenital anomalies and detects a genetic cause for these clinical features in 15-20% of cases (Manning, M. and Hudgins, L. Genet Med. 12:742-745, 2010).

NOTE: THERE WILL BE NO CHANGE TO REPORTABLES, FEES OR CPT CODES.